Company Overview - Mamei Biotechnology is a leading Chinese beauty company focused on providing anti-aging solutions, leveraging synthetic biology technology and over 20 years of experience in the anti-aging skincare industry [4] - The company has successfully developed recombinant double collagen, a unique engineered collagen that combines type I and type III collagen into a single molecule, enhancing its skincare products [4] - Mamei Biotechnology has been recognized as a key drafting unit for the industry standard "Recombinant Soluble Collagen" by the Ministry of Industry and Information Technology in 2023 [4] Market Position - According to Frost & Sullivan, Mamei has ranked first in the Chinese domestic eye care brand market by retail sales from 2021 to 2024 [5] - The brand "Lianhuo" ranks third among domestic foundation brands and fifth among all foundation brands in China, with a compound annual growth rate (CAGR) of 77.5% from 2022 to 2024, the highest among the top five foundation brands [5] Product Development - Mamei has established a comprehensive value chain covering basic research to application for its core ingredients, having developed over 80 proprietary ingredients, with more than 30 achieving large-scale production [7] - The company operates two production bases in Guangzhou, which are capable of high-density fermentation and purification processes for recombinant collagen production [7] Financial Performance - The company reported revenues of RMB 1.73 billion, RMB 2.23 billion, RMB 2.97 billion, and RMB 2.45 billion for the years ending December 31, 2022, 2023, 2024, and the nine months ending September 30, 2025, respectively [9] - The annual profits for the same periods were RMB 167.43 million, RMB 277.59 million, RMB 342.36 million, and RMB 246.65 million [10] - Gross profits for the respective years were RMB 1.17 billion, RMB 1.56 billion, RMB 2.18 billion, and RMB 1.83 billion [11] Industry Overview - The Chinese beauty industry is projected to grow from RMB 460.3 billion in 2019 to RMB 566.3 billion by 2024, with a CAGR of 4.2% [12] - The skincare market is expected to expand from RMB 355.9 billion in 2019 to RMB 451.4 billion by 2024, with a CAGR of 4.9% [15] - The makeup market is anticipated to grow from RMB 104.5 billion in 2019 to RMB 114.8 billion by 2024, with a CAGR of 1.9% [18]

Core Viewpoint - Mamei Biotechnology is a leading Chinese beauty company focused on anti-aging solutions, leveraging synthetic biology technology and core innovations in skincare products to drive growth in the industry [4][5]. Company Overview - Mamei Biotechnology has over 20 years of experience in the anti-aging skincare sector, emphasizing research and development, particularly in recombinant collagen technology [4]. - The company has developed recombinant double collagen, a unique engineered protein that combines type I and type III collagen into a single molecule, enhancing its product offerings [4]. - Mamei has been recognized as a key contributor to the industry standard for "recombinant soluble collagen" and is the only company in China approved as a national research center for recombinant functional protein technology [4][5]. Market Position - Mamei has ranked first in the Chinese eye care brand market from 2021 to 2024 based on retail sales, while its brand "Lianhuo" ranks third among domestic foundation brands and fifth overall in the foundation category [5]. - Lianhuo has achieved a compound annual growth rate (CAGR) of 77.5% in retail sales from 2022 to 2024, the highest among the top five foundation brands in China [5]. Product Development - The company has established a comprehensive value chain for core raw materials, developing over 80 proprietary ingredients, with more than 30 achieving large-scale production [7]. - Mamei operates two production bases in Guangzhou, which support high-density fermentation and purification processes for recombinant collagen production [7]. Financial Performance - Mamei's revenue for the fiscal years ending December 31 from 2022 to 2025 is projected to be RMB 1.73 billion, RMB 2.23 billion, RMB 2.97 billion, and RMB 2.45 billion respectively [8]. - The company reported profits of RMB 167.43 million, RMB 277.59 million, RMB 342.36 million, and RMB 246.65 million for the same periods [9]. - Gross profits for the same periods are RMB 1.18 billion, RMB 1.56 billion, RMB 2.18 billion, and RMB 1.83 billion respectively [10]. Industry Overview - The Chinese beauty market is projected to grow from RMB 460.3 billion in 2019 to RMB 566.3 billion by 2024, with a CAGR of 4.2% [10]. - The skincare market is expected to expand from RMB 355.9 billion in 2019 to RMB 451.4 billion by 2024, with a CAGR of 4.9% [13]. - The makeup market is anticipated to grow from RMB 104.5 billion in 2019 to RMB 114.8 billion by 2024, with a CAGR of 1.9% [16].

Group 1 - The core viewpoint of the article is that Guangdong Marubi Biotechnology Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with Goldman Sachs and CITIC Securities as joint sponsors [1] - Marubi Biotechnology is a leading Chinese beauty company focused on providing anti-aging solutions, leveraging synthetic biology technology and over 20 years of experience in the anti-aging skincare industry [1] - The company emphasizes research and development, particularly in core technologies such as recombinant collagen, to innovate skincare products with anti-wrinkle, firming, and repairing effects [1] Group 2 - According to a report by Frost & Sullivan, Marubi Biotechnology is the third largest beauty company in China in the recombinant collagen skincare segment, based on retail sales projected for 2024 [1]

Group 1 - The core viewpoint of the article is that Guangdong Marubi Biotechnology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with Goldman Sachs and CITIC Securities as joint sponsors [1] - Marubi Biotechnology is a leading Chinese beauty company focused on providing anti-aging solutions, leveraging synthetic biology technology and over 20 years of experience in the anti-aging skincare industry [1] - The company emphasizes research and development, particularly in core technologies such as recombinant collagen, to create skincare products with anti-wrinkle, firming, and repairing effects [1] Group 2 - According to a report by Frost & Sullivan, Marubi is the third largest beauty company in China in the recombinant collagen skincare segment, based on retail sales projected for 2024 [1]

据港交所文件：广东丸美生物技术股份有限公司向港交所提交上市申请书。 ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Guangdong Marubi Biotechnology Co., Ltd. 廣東丸美生物技術股份有限公司 (the "Company") (A joint stock company incorporated in the ...

香港聯合交易所有限公司及證券及期貨事務監察委員會對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表明概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Guangdong Marubi Biotechnology Co., Ltd. 廣東丸美生物技術股份有限公司 1 (a) 在聯交所網站登載本公告，並不會引致本公司、其聯席保薦人、整體協調 人、顧問或承銷團成員須於香港或任何其他司法權區進行發售或配發活動的 任何責任。概不保證本公司將會進行發售或配發； (b) 本公告所涉及的上市申請並未獲批准，聯交所及證監會或會接納、發回或拒 絕有關的公開發售及╱或上市申請； (c) 本公告不應被視為勸誘認購或購買任何證券，亦不擬構成該等勸誘； (d) 本公司或其任何聯屬人士、顧問或承銷團成員概無透過刊發本公告而於任何 司法權區發售任何證券或招攬要約認購或購買任何證券； (e) 本公告（及其所載資料）僅供參考，並不構成或組成在美國（包括其領土及屬 地、美國任何州及哥倫比亞特區）或有關要約或出售即屬違法的任何其他司 法權區發行或出售本公司任何證券的任何要約，或招攬購買、認購 ...

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 Guangdong Marubi Biotechnology Co., Ltd. 廣東丸美生物技術股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供信息予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣 下知悉、接納並向本公司、本公司的聯席保薦人、整體協調人、顧問或包銷團成員表示同意： 本公司招股章程根據香港法例第32章公司（清盤及雜項條文）條例送呈香港公司註冊處處長登記前，本公 司不會向香港公眾人士提出要約或邀請。倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請 僅依據向香港公司註冊處處長註冊的本公司招股章程作出投資決定；招股章程的文本將於發售期內向公眾 刊發。 (a) ...

Core Viewpoint - Lin Qingxuan has updated its IPO prospectus, including a name change from "Shanghai Lin Qingxuan Biotechnology Co., Ltd." to "Shanghai Lin Qingxuan Cosmetics Group Co., Ltd." This change has sparked discussions among investors regarding the strategic implications of moving from a biotechnology focus to a cosmetics brand, especially as the company approaches its IPO [1][2][3]. Financial Performance - Lin Qingxuan's revenue is projected to grow from approximately 6.91 billion yuan in 2022 to 12.1 billion yuan in 2024, indicating a steady upward trend [7]. - In the first half of this year, Lin Qingxuan reported revenue of about 10.52 billion yuan, a significant increase of 98.49% compared to the same period last year [8]. - The company's gross profit margins are notably high, with figures of 78.0%, 81.2%, 82.5%, and 82.4% for the years 2022 to 2024, outperforming major competitors [9]. Research and Development - Despite the high gross margins, Lin Qingxuan's R&D expenses have been relatively low, with rates of 3.06%, 2.45%, 2.51%, and 1.71% from 2022 to 2024, indicating a declining trend [10]. - The company has managed to maintain its high-end product sales without significant R&D investment, suggesting a potential reliance on marketing rather than innovation [11][19]. Marketing Strategy - Lin Qingxuan's marketing and distribution expenses have been substantial, with figures of 5.09 billion yuan, 4.86 billion yuan, and 6.88 billion yuan from 2022 to 2024, constituting a significant portion of total revenue [16]. - The marketing expenses have been approximately 9 to 20 times higher than R&D expenditures, highlighting a strategy focused on brand marketing over product development [16][18]. Market Position and Risks - The company has a heavy reliance on its core product, camellia oil, which accounted for 45.5% of revenue in the first half of this year, raising concerns about market risk due to limited product diversification [18]. - Recent investor behavior indicates a lack of confidence in Lin Qingxuan's IPO prospects, with early investors exiting before the IPO submission [21]. Future Outlook - Lin Qingxuan plans to expand its product line beyond camellia oil and implement a multi-brand strategy to enhance its market position [24]. - The company has maintained a growing number of physical stores, increasing from 366 to 554 over the past three years, which may provide a buffer against market fluctuations [26].

Investment Rating - The industry maintains a "Recommended" rating, with a focus on new consumption sectors such as beauty care, IP derivatives, and gold jewelry [5][29]. Core Insights - The report highlights significant growth in the beauty care sector, with Lin Qingxuan achieving a revenue of 1.052 billion yuan in the first half of 2025, marking a year-on-year increase of 98.3% and a net profit of 182 million yuan, up 109.9% [3][23]. - The retail sector saw a notable increase in Hainan's duty-free shopping, amounting to 2.38 billion yuan in November 2025, representing a 27.1% year-on-year growth [4][28]. - The travel sector is experiencing a surge in bookings for the New Year holiday, with overall reservation heat increasing by nearly 30% compared to the previous year [3][25]. Summary by Sections Market Performance - For the week of December 1-5, 2025, the performance of the retail, social services, and beauty care sectors was -0.83%, -0.65%, and -2.00% respectively, ranking 22nd, 20th, and 29th among 31 primary industries [14][16]. Key Industry Data and News - In the beauty care sector, the establishment of the world's first national standard for pig type I collagen purity was approved, marking a significant advancement in protein measurement [23]. - Galderma's Sculptra® received EU approval for new body indications, expanding its application [23]. - The travel sector saw Hubei Culture Tourism Group acquire a 29.99% stake in Junting Hotel for 1.499 billion yuan, becoming the controlling shareholder [24]. - The toy business of Qimeng Island reported a revenue of 127 million yuan for the third quarter of 2025, with a quarter-on-quarter growth of 93.3% [27]. Investment Recommendations - The report recommends focusing on companies such as Shangmei Co., Ltd., Juzhi Biotechnology, Marubi Biotechnology, Runben Co., Ltd., Proya, Chaohongji, and Furuida in the beauty care and new consumption sectors [5][29].